Sana Biotechnology reported a cash position of $153.1 million as of the third quarter of 2025, with a pro forma cash balance of $170.5 million including recent at-the-market offering activity. The company raised $115.8 million in aggregate gross proceeds from sales of common stock in the third quarter of 2025. Non-cash expenses related to research and development success payments and contingent consideration totaled $3.1 million for the quarter and $15.3 million for the nine months ended September 30, 2025. Sana recorded a non-cash impairment of long-lived assets of $44.6 million for the nine-month period, primarily related to its manufacturing facility in Bothell, Washington, and certain laboratory and office space in Seattle, Washington. The company has suspended internal investment in allogeneic CAR T studies and further build-out of internal manufacturing capabilities, shifting focus to SC451 for type 1 diabetes and SG293 for in vivo CAR T programs. Sana expects its cash runway to extend into late 2026.